Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Paris 2024 Olympics a risky business
How can excellence in sport be insured, when this ideal is confronted to the harsh reality of multiple pressures: socio-political, technology, clima
COP29 and lessons for investors
COP29 faced criticisms around lobbying and lack of scale of action, but some important agreements were completed. For example, $300bn per year for dev
Navigating changes to Solvency II for UK insurers
The UK’s solvency regulations are amended by PS15/24, released by the Prudential Regulation Authority (PRA) in November 2024. With changes to reportin

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.